Cytochrome P450 2B6 is anenzyme that in humans is encoded by theCYP2B6gene.[5] CYP2B6 is a member of thecytochrome P450 group of enzymes. Along withCYP2A6, it is involved with metabolizingnicotine, along with many other substances.[5]
This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins aremonooxygenases which catalyze many reactions involved in drugmetabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to theendoplasmic reticulum and its expression is induced byphenobarbital. The enzyme is known to metabolize somexenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide.[5]
Transcript variants for this gene have been described; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely relatedpseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.[5]
^Alkattan, A., & Alsalameen, E. (2021). Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment. Expert opinion on drug metabolism & toxicology, 10.1080/17425255.2021.1925249. Advance online publication.https://doi.org/10.1080/17425255.2021.1925249
^Rao LK, Flaker AM, Friedel CC, Kharasch ED (December 2016). "Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance".Anesthesiology.125 (6):1103–1112.doi:10.1097/ALN.0000000000001392.PMID27763887.S2CID41380105.
^Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (July 2013). "Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn".Analytical and Bioanalytical Chemistry.405 (19):6307–21.doi:10.1007/s00216-013-7051-6.PMID23774830.S2CID27966043.
^abcdefWalsky RL, Astuccio AV, Obach RS (December 2006). "Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6".Journal of Clinical Pharmacology.46 (12):1426–38.doi:10.1177/0091270006293753.PMID17101742.S2CID40915941.
^Obach RS, Cox LM, Tremaine LM (February 2005). "Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study".Drug Metabolism and Disposition.33 (2):262–70.doi:10.1124/dmd.104.002428.PMID15547048.S2CID7254643.
^Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL (1997). "Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter".Pharmacotherapy.17 (6):1238–45.doi:10.1002/j.1875-9114.1997.tb03087.x.PMID9399606.S2CID20269145.
^Guo Z, Raeissi S, White RB, Stevens JC (March 1997). "Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes".Drug Metabolism and Disposition.25 (3):390–3.PMID9172960.
^Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP (June 2007). "Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products".Toxicology.235 (1–2):83–91.Bibcode:2007Toxgy.235...83A.doi:10.1016/j.tox.2007.03.007.PMID17433521.
^abcdeHesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (October 2000). "CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants".Drug Metabolism and Disposition.28 (10):1176–83.PMID10997936.
Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E (November 2010). "Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients".Clinical Pharmacology and Therapeutics.88 (5):676–84.doi:10.1038/clpt.2010.172.PMID20881953.S2CID24749169.
Smith G, Stubbins MJ, Harries LW, Wolf CR (December 1998). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily".Xenobiotica; the Fate of Foreign Compounds in Biological Systems.28 (12):1129–65.doi:10.1080/004982598238868.PMID9890157.
Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P (March 2011). "CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility".Annals of Hematology.90 (3):293–9.doi:10.1007/s00277-010-1085-z.PMID20878158.S2CID19318796.
Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (January 2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants".Pharmacogenetics.14 (1):1–18.doi:10.1097/00008571-200401000-00001.PMID15128046.
Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF (September 2009). "Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6".Current Drug Metabolism.10 (7):730–53.doi:10.2174/138920009789895534.PMID19702527.
Cabrera Figueroa S, Fernández de Gatta M, Hernández García L, Domínguez-Gil Hurlé A, Bustos Bernal C, Sepúlveda Correa R, García Sánchez MJ (October 2010). "The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy".Therapeutic Drug Monitoring.32 (5):579–85.doi:10.1097/FTD.0b013e3181f0634c.PMID20720517.S2CID24793535.
Shimada M, Miyagawa T, Kawashima M, Tanaka S, Honda Y, Honda M, Tokunaga K (October 2010). "An approach based on a genome-wide association study reveals candidate loci for narcolepsy".Human Genetics.128 (4):433–41.doi:10.1007/s00439-010-0862-z.PMID20677014.S2CID24207887.
Lindfelt T, O'Brien J, Song JC, Patel R, Winslow DL (October 2010). "Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms".The Annals of Pharmacotherapy.44 (10):1572–8.doi:10.1345/aph.1P141.PMID20841522.S2CID24188775.
Chung JY, Cho JY, Lim HS, Kim JR, Yu KS, Lim KS, Shin SG, Jang IJ (January 2011). "Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin".Drug Metabolism and Disposition.39 (1):92–7.doi:10.1124/dmd.110.035246.PMID20876786.S2CID15380723.
Lampreabe I, Gainza de los Rios FJ, Arrieta Gutiérrez A, Jofre-Monseny L, Rodriguez M, Amenabar Iribar JJ, Zárraga Larrondo S, Tejedor D, Martinez A, Olano-Martin E (October 2010). "Toward personalized medicine in renal transplantation".Transplantation Proceedings.42 (8):2864–7.doi:10.1016/j.transproceed.2010.08.009.PMID20970553.
Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V (September 2010). "Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients".Pharmacogenomics.11 (9):1223–34.doi:10.2217/pgs.10.94.PMID20860463.
This article incorporatespublic domain material from"Entrez Gene: cytochrome P450".Reference Sequence collection.National Center for Biotechnology Information.
